A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Gynecologic Oncology(2020)
摘要
•This is the first study to combine ralimetinib with gemcitabine and carboplatin.•Modest improvement in PFS was seen with ralimetinib combination and maintenance therapy versus standard-of-care.•The safety profile of ralimetinib combination therapy was mainly consistent with safety of the chemotherapy backbone alone.•Grade 3/4 elevated alanine aminotransferase was more common in the ralimetinib arm.
更多查看译文
关键词
Ovarian cancer,Clinical trial,p38 mitogen-activated protein kinase,Small-molecule inhibitor
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络